Raoul Pal backs ETH: According to current trends, it is expected to outperform BTC over time
BlockBeats news, on April 8, former Goldman Sachs executive, author of "The Global Macro Investor", and Real Vision co-founder and CEO Raoul Pal posted on social media saying, "The ETH/BTC exchange rate has now become very interesting, which is consistent with the upward trend of the business cycle (rising ISM) and liquidity. From a long-term chart perspective, the trend remains very constructive. Since 2017, ETH has largely maintained its value relative to BTC; if this chart continues following the current trend, ETH should outperform BTC over time."
This also makes sense intuitively: as a smart contract platform, ETH's total addressable market (TAM) is fundamentally different from BTC's 'store of value' attribute. BTC mainly carries the total value of savings, while ETH can carry the value of economic activity itself. Because of this difference, over time, the dominance of smart contracts relative to BTC will continue to increase."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
